Alto Neuroscience Reports Q1 2026 Results, Extends Cash Runway to 2029, Delays Some Trial Readouts
ANRO has more than doubled off its 52-week low of $2.15.
Summary
Alto Neuroscience reported increased Q1 2026 net losses but significantly extended its cash runway to 2029, while also announcing delays for some key clinical trial readouts.
Key Events · Earnings and Guidance · ANRO
-
Q1 2026 Financial Results
The company reported a net loss of $26.2 million for the quarter ended March 31, 2026, compared to a net loss of $15.2 million for the same period in 2025. R&D expenses increased to $20.3 million from $10.0 million year-over-year.
-
Extended Cash Runway
Alto Neuroscience's cash, cash equivalents, and restricted cash totaled approximately $264.2 million as of March 31, 2026. This balance is expected to fund planned operations through 2029, including a potential NDA submission for ALTO-207.
-
ALTO-207 Phase 2b Trial Initiated
The company initiated a Phase 2b clinical trial for ALTO-207 in treatment-resistant depression (TRD), with a Phase 3 trial planned for early 2027 and Phase 2b readout guided for 2H 2027.
-
ALTO-300 and ALTO-100 Trial Delays
Topline data readouts for the ALTO-300 MDD trial and ALTO-100 bipolar depression trial are now expected in 1H 2027 and mid-2027, respectively, due to enhanced eligibility review and patient quality measures.
Analysis · ANRO · Life Sciences
Alto Neuroscience reported a net loss of $26.2 million for Q1 2026, an increase from the prior year. However, the company's cash balance of $264.2 million, bolstered by a recent $120 million private placement, is now projected to fund operations through 2029. This extended cash runway is a critical de-risking factor for a clinical-stage biotech. While the ALTO-207 program is progressing with a Phase 2b trial initiated, the company also announced delays for ALTO-300 and ALTO-100 trial readouts, pushing back potential catalysts. New analyses for ALTO-101, which previously failed its primary endpoint, suggest potential in other cognitive disorders, indicating an effort to salvage value from the program.
At the time of this filing, ANRO was trading at $24.39 on NYSE in the Life Sciences sector, with a market capitalization of approximately $786.8M. The 52-week trading range was $2.15 to $28.44. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.